Stopping or continuing hormone pill for low-grade uterine cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether it is better to stop a hormone tablet (an aromatase inhibitor) versus keep taking it in people with low-grade endometrial stromal sarcoma whose cancer is currently controlled. It may help find the safest way to maintain disease control while avoiding unnecessary treatment if stopping is possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your tumor has been confirmed as low-grade endometrial stromal sarcoma
- Your cancer is either advanced in the body or has spread, or it was found to have extended during surgery
- You have been taking an aromatase inhibitor (anastrozole, exemestane, or letrozole) long enough (about 24 months if no measurable cancer, or 36 months if measurable cancer)
- At the time of study entry, the cancer is controlled (no major growth—either stable or shrunk) on that hormone pill
- You can do daily activities at least fairly well (ECOG score 0–2), and you agree to join after informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of two oral drugs, elacestrant and everolimus, for advanced or recurrent endometrial cancer that is hormone receptor positive. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests whether elacestrant, a drug that blocks estrogen, can help people with certain types of uterine sarcoma that have strong estrogen receptors. It may slow or stop cancer growth in tumors that rely on estrogen.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
Hear when a new Low Grade Endometrial Stromal Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.